Form 8-K - Current report:
SEC Accession No. 0001558370-22-010589
Filing Date
2022-07-08
Accepted
2022-07-08 17:00:20
Documents
12
Period of Report
2022-07-08
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20220708x8k.htm   iXBRL 8-K 52139
  Complete submission text file 0001558370-22-010589.txt   178434

Data Files

Seq Description Document Type Size
2 EX-101.SCH kala-20220708.xsd EX-101.SCH 3130
3 EX-101.LAB kala-20220708_lab.xml EX-101.LAB 15922
4 EX-101.PRE kala-20220708_pre.xml EX-101.PRE 10057
6 EXTRACTED XBRL INSTANCE DOCUMENT kala-20220708x8k_htm.xml XML 4822
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 221075146
SIC: 2834 Pharmaceutical Preparations